The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded versions due to regulatory changes.

Those rehired by the Trump administration include at least 10 FDA staffers responsible for reviewing the safety of new food ...

Hims stock plunged Tuesday after the compounding pharmacy issued a bullish outlook that still includes knockoff versions of ...

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

The Trump administration has started rehiring some of the FDA employees it fired last week, the latest chapter in a haphazard ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.

Ignore social media posts attributing false quote about counterfeit drugs to head of Nigeria's drug control agency IN SHORT: The claim that the director general of Nigeria's food and drug control ...